Quantcast

Latest National Institute of Allergy and Infectious Diseases Stories

Child Believed To Be Cured Of HIV Now Has Detectable Virus Levels
2014-07-11 07:38:26

redOrbit Staff & Wire Reports - Your Universe Online The Mississippi infant believed to have been cured of HIV following an extended remission now once again has “detectable levels” of the AIDS-causing virus in her blood, the US National Institute of Allergy and Infectious Diseases (NIAID) has confirmed. The child was born prematurely in 2010 to an HIV-infected mother who had not been diagnosed until the time of delivery and had not been given antiretroviral medication during...

2014-07-07 12:29:07

Prestigious Biomedical Researcher and Author Joins Innovator in DNA Capture Technology SAN DIEGO, July 7, 2014 /PRNewswire/ -- Diomics, an innovator in DNA capture technology, today announced the appointment of Thomas Kindt, Ph.D., as Diomic's chief scientific officer (CSO) effective July 7, 2014. Dr. Kindt brings more than 30 years of relevant industry experience to his new role having previously served as Director of Intramural Research of the National Institute of Allergy and...

2014-07-01 08:30:44

SAN DIEGO, July 1, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB(®) library and proprietary antibody conjugation technology platforms have...

2014-06-05 12:29:58

Center will utilize next generation genomic sequencing and analysis technologies to better understand infectious disease pathogens, and create resource for the research community ROCKVILLE, Md. and LA JOLLA, Calif., June 5, 2014 /PRNewswire-USNewswire/ -- Scientists from the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, have been awarded a five year grant from the NIH's National Institute of Allergy and Infectious Diseases (NIAID) to establish and operate a...

2014-05-21 13:42:09

NIH Research by NIH Scientists, Grantees Identifies Leads for Further Study WHAT: Clinicians treating patients suffering from Middle East respiratory syndrome (MERS) currently have no drugs specifically targeted to the MERS coronavirus (MERS-CoV), a virus first detected in humans in 2012 that has since caused 614 laboratory-confirmed infections, including 181 that were fatal, according to the World Health Organization. The case count escalated sharply in the spring of this year, and...

2014-05-12 08:31:13

PRINCETON, N.J., May 12, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the first quarter ended March 31, 2014. Soligenix's revenues for the quarter ended March 31, 2014 were $0.9 million as...

2014-04-02 16:31:07

ROCKVILLE, Md., April 2, 2014 /PRNewswire-USNewswire/ -- Sanaria received the 2014 Vaccine Industry Excellence Award for the "Best Prophylactic Vaccine" at a ceremony held March 25 in Washington DC during the 14th World Vaccine Congress. Vaccines from Sanofi Pasteur, GSK, and Novartis were among the 6 finalists competing with Sanaria. The awardee, Sanaria® PfSPZ Vaccine, demonstrated complete protection against malaria in all volunteers (6/6) who received high dose immunizations in a...

2014-03-26 08:28:41

PRINCETON, N.J., March 26, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013. Soligenix's revenues for the year ended were $3.2 million as compared to $3.1 million for...

Robust Research Efforts Needed To Address Challenge Of Antimicrobial Resistance
2014-03-20 16:17:43

NIH/National Institute of Allergy and Infectious Diseases JAMA commentary and NIAID report discuss research priorities to improve prevention, diagnosis and treatment Given the evolutionary ability of microbes to rapidly adapt, the threat of antimicrobial resistance likely will never be eliminated. Today, many factors compound the problem, including the inappropriate use of antibiotics and a dwindling supply of new medicines, leading to a global crisis of antimicrobial resistance. This...

2014-03-11 08:29:04

Presentation on March 25, 2014 at 2:10 PM EDT PRINCETON, N.J., March 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related